Drug reference

vorapaxar

Protease-activated receptor-1 (PAR-1) inhibitor · Antiplatelet

Protease-activated receptor-1 (PAR-1) inhibitorAntiplatelet

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

12 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 12 →

AbciximabSevereDatabaseDDInter
AcalabrutinibSevereDatabaseDDInter
AlteplaseSevereDatabaseDDInter
AmprenavirSevereDatabaseDDInter

Mechanism

Not yet extracted

Indications

reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral artery diseasesecondary prevention in patients with a history of myocardial infarction or peripheral artery disease

Dosing

Adult: Given orally in combination with either aspirin or clopidogrel.

Pharmacokinetics

Onset

rapid onset of action

Duration

effect on thrombin-induced platelet aggregation can persist for up to 4 weeks after the drug is stopped (due to tight binding to PAR-1)

Half-life

3 to 4 days (circulating)

Bioavailability

90%

Metabolism

metabolized in the liver by CYP3A4

Contraindications

history of intracranial bleeding
stroke
transient ischemic attack
cerebrovascular disease
prior intracranial bleed

Side effects

Common

bleeding (increased risk)

Serious

Bleeding
Intracranial bleeding (doubled risk compared to placebo)
Moderate or severe bleeding

Drug interactions

Abciximab

Severe

Database

Clinical effect not specified

Source: DDInter

Acalabrutinib

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Alteplase

Severe

Database

Clinical effect not specified

Source: DDInter

Amprenavir

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Anagrelide

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Anisindione

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Anistreplase

Severe

Database

Clinical effect not specified

Source: DDInter

Antithrombin Alfa

Severe

Database

Clinical effect not specified

Source: DDInter

Antithrombin Iii Human

Severe

Database

Clinical effect not specified

Source: DDInter

Apalutamide

Severe

Database

Drug interaction classified as: metabolism

Source: DDInter

Apixaban

Severe

Database

Drug interaction classified as: synergy

Source: DDInter

Ardeparin

Severe

Database

Clinical effect not specified

Source: DDInter

Related guidelines

Cardiovascular disease prevention

ESC · Cardiology · 2021

Primary prevention of cardiovascular disease

AHA · Cardiology · 2019

Stroke and TIA — secondary prevention

AHA · Neurology · 2021

ST-elevation myocardial infarction

CSI · Cardiology · 2020

Dyslipidaemia management

ICMR · Cardiology · 2023

Ask House about vorapaxar

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Textbook-sourced·Sources: Goodman & Gilman 14e, Harrison 22e·Updated: 2026-05-10